%0 Journal Article
%T The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease
%A Angelika Caputo
%A Carolyn Langlois
%A Cristina Lopez Lopez
%A Eric M. Reiman
%A Fonda Liu
%A J. Michael Ryan
%A Jessica B. Langbaum
%A Marie-Emmanuelle Riviere
%A Marie-Laure Rouzade-Dominguez
%A Martin Zalesak
%A Pierre N. Tariot
%A Rob Lenz
%A Ronald G. Thomas
%A Suzanne Hendrix
%A Vissia Viglietta
%J Archive of "Alzheimer's & Dementia : Translational Research & Clinical Interventions".
%D 2019
%R 10.1016/j.trci.2019.02.005
%X Alzheimer's disease (AD) pathology, including the accumulation of amyloid beta (A¦Â) species and tau pathology, begins decades before the onset of cognitive impairment. This long preclinical period provides an opportunity for clinical trials designed to prevent or delay the onset of cognitive impairment due to AD. Under the umbrella of the Alzheimer's Prevention Initiative Generation Program, therapies targeting A¦Â, including CNP520 (umibecestat), a ¦Â-site-amyloid precursor protein cleaving enzyme-1 (BACE-1) inhibitor, and CAD106, an active A¦Â immunotherapy, are in clinical development in preclinical AD
%K Alzheimer's disease
%K Preclinical Alzheimer's disease
%K Mild cognitive impairment
%K Umibecestat
%K CNP520
%K BACE-1 inhibitor
%K CAD106
%K Generation Program
%K Alzheimer's prevention initiative
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562315/